R
Renate Solf
Researcher at Novartis
Publications - 5
Citations - 327
Renate Solf is an academic researcher from Novartis. The author has contributed to research in topics: Concanavalin A & Swainsonine. The author has an hindex of 4, co-authored 5 publications receiving 322 citations.
Papers
More filters
Journal ArticleDOI
Swainsonine: an inhibitor of glycoprotein processing.
TL;DR: Cells grown in the alkaloid showed an increased capacity to bind Escherichia coli B886, a bacterium that binds to high mannose glycoproteins, and an increasing binding of [3H]concanavalin A.
Journal ArticleDOI
Effect of swainsonine, an inhibitor of glycoprotein processing, on cultured mammalian cells.
TL;DR: Swainsonine is an indolizidine alkaloid that inhibits glycoprotein processing by inhibiting mannosidase II as discussed by the authors, and has been shown to be cytotoxic to mammalian cells.
Journal ArticleDOI
Resistance of Escherichia coli to rifampicin and sorangicin A--a comparison.
TL;DR: Parallel investigations with rifampicin revealed partial cross-resistance, which was more marked in sorangicin A-resistant mutants than in rifampsicin- resistant mutants.
Journal ArticleDOI
Michaelis‐Menten kinetic analysis of Escherichia coli SS142 adhesion to intestine 407 monolayers
Paul S. Cohen,Alan D. Elbein,Renate Solf,Helmut Mett,Janos Regös,Eva Brigitte Menge,Klaus Vosbeck +6 more
Journal ArticleDOI
Quantitation of the rate of ingestion of Escherichia coli by human polymorphonuclear neutrophils using [3H]uracil
TL;DR: It was shown that although about 5% of ingested E. coli B-1385 remained viable for at least 3 h after being ingested by PMN, the surviving bacteria may have become damaged as shown by a decreased ability to incorporate [ 3 H]uracil into RNA when released from PMN.